Moving toward Personalized Medicine in the Methadone Maintenance Treatment Program: A Pilot Study on the Evaluation of Treatment Responses in Taiwan
Table 3
Influence of CYP2B6, CYP2C19, and ABCB1 polymorphism on methadone plasma concentrations ()a.
Gene
(%)
Dose (SD)
R,S-Methadoneb (SD)
R-Methadoneb (SD)
S-Methadoneb (SD)
CYP2B6 genotype
A785G (*4)
A/A
101 (57.4)
51.4 (26.5)
5.35 (0.81)
4.32 (0.69)
4.15 (0.67)
A/G
61 (34.6)
52.6 (38.2)
5.22 (0.81)
4.21 (0.66)
4.05 (0.72)
G/G
14 ( 8.0)
40.9 (18.4)
5.84 (0.77)
4.60 (0.79)
4.52 (0.89)
value
—
0.42
0.03*
0.15
0.08
G516T (*9)
G/G
124 (70.5)
50.4 (24.9)
5.28 (0.82)
4.29 (0.67)
4.10 (0.67)
G/T
46 (26.1)
54.4 (43.1)
5.42 (0.76)
4.29 (0.70)
4.21 (0.78)
T/T
6 (3.4)
36.7 (19.7)
5.99 (0.99)
4.57 (0.99)
4.57 (1.02)
value
—
0.38
0.09
0.63
0.22
CYP2C19 genotype
G651A (*2)
G/G
90 (51.1)
52.6 (35.2)
5.40 (0.79)
4.33 (0.74)
4.18 (0.78)
G/A
77 (43.8)
49.8 (24.9)
5.28 (0.86)
4.29 (0.62)
4.12 (0.64)
A/A
9 (5.1)
45.2 (26.8)
5.38 (0.68)
4.24 (0.72)
3.95 (0.62)
P value
—
0.71
0.66
0.90
0.60
G636A (*3)
G/G
158 (89.8)
52.1 (31.3)
5.33 (0.83)
4.30 (0.69)
4.15 (0.70)
G/A
16 (9.1)
39.1 (20.9)
5.48 (0.70)
4.28 (0.64)
4.08 (0.87)
A/A
2 (1.1)
62.5 (31.8)
5.81 (0.13)
4.85 (0.16)
4.40 (0.66)
value
—
0.24
0.55
0.52
0.81
C3402T (*17)
C/C
174 (98.9)
49.9 (26.7)
5.35 (0.82)
4.30 (0.69)
4.15 (0.72)
C/T
2 (1.1)
140 (155.6)
4.55 (0.32)
4.18 (0.53)
3.79 (0.91)
T/T
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
value
—
<0.0001*
0.08
0.81
0.47
ABCB1 genotype
C1236T
C/C
19 (10.8)
67.9 (50.4)
5.23 (0.66)
4.36 (0.52)
4.21 (0.48)
C/T
80 (45.5)
50.4 (28.3)
5.38 (0.82)
4.29 (0.73)
4.17 (0.72)
T/T
77 (43.7)
47.2 (24.7)
5.37 (0.85)
4.29 (0.68)
4.10 (0.76)
value
—
0.02*
0.75
0.91
0.79
G2677T
G/G
48 (27.3)
49.6 (39.4)
5.23 (0.86)
4.12 (0.76)
4.00 (0.68)
G/T
84 (47.7)
53.1 (27.3)
5.24 (0.73)
4.26 (0.62)
4.08 (0.67)
T/T
44 (25.0)
48.5 (25.5)
5.67 (0.86)
4.58 (0.65)
4.41 (0.77)
value
—
0.68
0.008*
0.004*
0.01*
C3435T
C/C
69 (39.2)
56.8 (39.3)
5.26 (0.87)
4.31 (0.69)
4.13 (0.63)
C/T
83 (47.2)
47.1 (21.6)
5.36 (0.74)
4.26 (0.71)
4.12 (0.76)
T/T
24 (13.6)
47.7 (26.9)
5.52 (0.91)
4.49 (0.58)
4.27 (0.78)
value
—
0.13
0.41
0.36
0.63
No available data on genotype for two subjects due to methodological problems.
bR,S-Methadone, R-methadone, and S-methadone plasma concentrations were divided by the methadone dose (in milligrams per day) and by the patient weight (in kilograms). The unit of concentration is ng·kg/mL·mg. Then, the values were natural log transformed before analysis. All values are expressed as the mean and standard deviation (SD).
*Statistical significance set at ; comparisons were performed by the t-test, ANOVA, Mann-Whitney U test, or Kruskal-Wallis test as appropriate.
